20.02
5.43%
-1.15
Pre-market:
20.04
0.02
+0.10%
Intellia Therapeutics Inc stock is currently priced at $20.02, with a 24-hour trading volume of 1.43M.
It has seen a -5.43% decreased in the last 24 hours and a -25.38% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $21.31 pivot point. If it approaches the $20.19 support level, significant changes may occur.
Previous Close:
$21.17
Open:
$20.53
24h Volume:
1.43M
Market Cap:
$1.92B
Revenue:
$36.28M
Net Income/Loss:
$-481.19M
P/E Ratio:
-3.6667
EPS:
-5.46
Net Cash Flow:
$-408.07M
1W Performance:
-6.10%
1M Performance:
-25.38%
6M Performance:
-17.88%
1Y Performance:
-44.80%
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 Erie Street, Suite 130, Cambridge, MA
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
Apr-13-23 | Initiated | Canaccord Genuity | Buy |
Mar-21-23 | Initiated | Bernstein | Outperform |
Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Oct-11-22 | Initiated | Morgan Stanley | Overweight |
Sep-21-22 | Initiated | JP Morgan | Overweight |
Sep-01-22 | Initiated | Citigroup | Sell |
Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
Jun-16-22 | Initiated | BofA Securities | Buy |
Apr-28-22 | Initiated | Credit Suisse | Outperform |
Feb-18-22 | Initiated | William Blair | Outperform |
Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
Jan-31-22 | Initiated | Cowen | Outperform |
Jan-07-22 | Initiated | Piper Sandler | Overweight |
Oct-05-21 | Initiated | Guggenheim | Buy |
Sep-24-21 | Initiated | Stifel | Buy |
Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
Jun-11-21 | Initiated | H.C. Wainwright | Buy |
May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
May-04-21 | Initiated | RBC Capital Mkts | Outperform |
Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Oct-27-20 | Initiated | Truist | Buy |
Oct-14-20 | Initiated | Wells Fargo | Overweight |
Sep-18-20 | Initiated | Goldman | Buy |
Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jul-09-19 | Initiated | Robert W. Baird | Outperform |
Jun-10-19 | Initiated | ROTH Capital | Neutral |
May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
Apr-12-19 | Initiated | Evercore ISI | Outperform |
Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
Oct-29-18 | Initiated | Credit Suisse | Neutral |
Sep-21-18 | Initiated | Raymond James | Mkt Perform |
May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
Nov-01-17 | Reiterated | Jefferies | Buy |
Jun-22-17 | Resumed | Jefferies | Buy |
Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
Zacks Investment Research
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline
Zacks Investment Research
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
Seeking Alpha
2 Stocks Down 30% to Buy Right Now
The Motley Fool
Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.
The Motley Fool
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
The Motley Fool
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Intellia Therapeutics Inc (NTLA) Revenue 2024
NTLA reported a revenue (TTM) of $36.27 million for the quarter ending December 31, 2023, a -30.40% decline year-over-year.
Intellia Therapeutics Inc (NTLA) Net Income 2024
NTLA net income (TTM) was -$481.19 million for the quarter ending December 31, 2023, a -1.48% decrease year-over-year.
Intellia Therapeutics Inc (NTLA) Cash Flow 2024
NTLA recorded a free cash flow (TTM) of -$408.07 million for the quarter ending December 31, 2023, a -4.19% decrease year-over-year.
Intellia Therapeutics Inc (NTLA) Earnings per Share 2024
NTLA earnings per share (TTM) was -$5.41 for the quarter ending December 31, 2023, a +12.46% growth year-over-year.
About Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):